Cigna Investments’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Sell |
19,319
-201
| -1% | -$11.5K | 0.14% | 118 |
|
|
2026
Q1 | $1.18M | Hold |
19,520
| – | – | 0.18% | 101 |
|
|
2025
Q4 | $1.05M | Sell |
19,520
-485
| -2% | -$23.3K | 0.15% | 120 |
|
|
2025
Q3 | $902K | Hold |
20,005
| – | – | 0.13% | 143 |
|
|
2025
Q2 | $926K | Sell |
20,005
-378
| -2% | -$18.6K | 0.16% | 134 |
|
|
2025
Q1 | $1.24M | Sell |
20,383
-398
| -2% | -$23.2K | 0.23% | 91 |
|
|
2024
Q4 | $1.18M | Sell |
20,781
-125
| -0.6% | -$6.98K | 0.21% | 96 |
|
|
2024
Q3 | $1.08M | Sell |
20,906
-461
| -2% | -$21.6K | 0.19% | 108 |
|
|
2024
Q2 | $888K | Sell |
21,367
-145
| -0.7% | -$6.49K | 0.16% | 124 |
|
|
2024
Q1 | $1.17M | Sell |
21,512
-269
| -1% | -$13.7K | 0.22% | 96 |
|
|
2023
Q4 | $1.12M | Sell |
21,781
-683
| -3% | -$35.9K | 0.23% | 94 |
|
|
2023
Q3 | $1.3M | Sell |
22,464
-3,047
| -12% | -$187K | 0.3% | 64 |
|
|
2023
Q2 | $1.63M | Sell |
25,511
-355
| -1% | -$23.8K | 0.3% | 58 |
|
|
2023
Q1 | $1.79M | Sell |
25,866
-513
| -2% | -$36.2K | 0.36% | 53 |
|
|
2022
Q4 | $1.9M | Buy |
26,379
+141
| +0.5% | +$10.6K | 0.39% | 48 |
|
|
2022
Q3 | $1.87M | Sell |
26,238
-1,457
| -5% | -$106K | 0.41% | 45 |
|
|
2022
Q2 | $2.13M | Sell |
27,695
-11,451
| -29% | -$872K | 0.42% | 46 |
|
|
2022
Q1 | $2.86M | Sell |
39,146
-11,462
| -23% | -$770K | 0.35% | 58 |
|
|
2021
Q4 | $3.16M | Sell |
50,608
-17,651
| -26% | -$1.04M | 0.25% | 68 |
|
|
2021
Q3 | $4.04M | Sell |
68,259
-1,546
| -2% | -$102K | 0.3% | 64 |
|
|
2021
Q2 | $4.67M | Sell |
69,805
-11,020
| -14% | -$719K | 0.33% | 58 |
|
|
2021
Q1 | $5.1M | Buy |
80,825
+1,712
| +2% | +$107K | 0.35% | 61 |
|
|
2020
Q4 | $4.91M | Buy |
79,113
+6,013
| +8% | +$370K | 0.38% | 53 |
|
|
2020
Q3 | $4.41M | Sell |
73,100
-3,446
| -5% | -$207K | 0.42% | 48 |
|
|
2020
Q2 | $4.5M | Buy |
76,546
+10,164
| +15% | +$608K | 0.43% | 47 |
|
|
2020
Q1 | $3.7M | Buy |
66,382
+1,077
| +2% | +$65.8K | 0.48% | 41 |
|
|
2019
Q4 | $4.11M | Buy |
65,305
+17,288
| +36% | +$990K | 0.43% | 42 |
|
|
2019
Q3 | $2.75M | Buy |
48,017
+2,417
| +5% | +$114K | 0.28% | 75 |
|
|
2019
Q2 | $2.02M | Sell |
45,600
-1,500
| -3% | -$69.9K | 0.22% | 97 |
|
|
2019
Q1 | $2.25M | Sell |
47,100
-3,331
| -7% | -$166K | 0.25% | 79 |
|
|
2018
Q4 | $2.62M | Buy |
50,431
+1,124
| +2% | +$60.4K | 0.22% | 63 |
|
|
2018
Q3 | $2.49M | Sell |
49,307
-16,088
| -25% | -$955K | 0.2% | 75 |
|
|
2018
Q2 | $3.62M | Sell |
65,395
-7,963
| -11% | -$430K | 0.26% | 54 |
|
|
2018
Q1 | $4.64M | Sell |
73,358
-712
| -1% | -$45.8K | 0.31% | 44 |
|
|
2017
Q4 | $4.54M | Sell |
74,070
-2,628
| -3% | -$164K | 0.3% | 46 |
|
|
2017
Q3 | $4.89M | Sell |
76,698
-1,170
| -2% | -$68.3K | 0.33% | 40 |
|
|
2017
Q2 | $4.34M | Buy |
77,868
+9,200
| +13% | +$501K | 0.3% | 46 |
|
|
2017
Q1 | $3.73M | Buy |
68,668
+7,051
| +11% | +$387K | 0.26% | 51 |
|
|
2016
Q4 | $3.6M | Buy |
+61,617
| New | +$3.37M | 0.39% | 48 |
|
Other funds holding BMY
AIM
FWIA
DLA
Cigna Investments's BMY Position: Q2 2026 in Review
Cigna Investments reduced its Bristol-Myers Squibb (BMY) stake by 1% in Q2 2026, selling an estimated $11.5K and leaving 19,319 shares worth $1.11M. The position accounts for 0.14% of the portfolio, ranked #118.
Cigna Investments first reported a position in BMY in Q4 2016 and has held it in 39 quarters since. The position peaked at $5.1M in Q1 2021. 891 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Cigna Investments held 19,319 shares of Bristol-Myers Squibb worth $1.11M as of Q2 2026.
- Cigna Investments sold 201 Bristol-Myers Squibb shares in Q2 2026, an estimated $11.5K.
- Bristol-Myers Squibb made up 0.14% of Cigna Investments's portfolio in Q2 2026, its #118 holding.
- Cigna Investments first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 39 quarters since.
- Cigna Investments's Bristol-Myers Squibb position peaked at $5.1M in Q1 2021.
- 891 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Cigna Investments's 13F filing for Q2 2026, filed 21 Jul 2026.